Free Trial
OTCMKTS:CYTR

LadRx (CYTR) Stock Price, News & Analysis

LadRx logo

About LadRx Stock (OTCMKTS:CYTR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,000 shs
Average Volume
99,706 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Stock News Headlines

Reviewing CERo Therapeutics (NASDAQ:CERO) & LadRx (OTCMKTS:CYTR)
Memorial Day Sale! 82% Off Disruptors and Dominators!
Nvidia's robot breakthrough, unveiled by CEO Jensen Huang at CES, could spark a $24T revolution. He said the "ChatGPT moment" for robotics is near. I believe the lives of 65M Americans could be impacted – this year. And one $7 stock could be the biggest winner.
Lord Abbett Developing Growth R3 (LADRX)
Lord Abbett Developing Growth R3
Lord Abbett Developing Growth Fund;R3
See More Headlines

CYTR Stock Analysis - Frequently Asked Questions

LadRx Co. (OTCMKTS:CYTR) announced its earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02.

Shares of LadRx reverse split on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Biopharmx (BPMX), SELLAS Life Sciences Group (SLS), Rexahn Pharmaceuticals (REXN), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA) and Protalix BioTherapeutics (PLX).

Company Calendar

Last Earnings
8/09/2019
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:CYTR
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.24 per share
Price / Book
N/A

Miscellaneous

Free Float
33,834,000
Market Cap
$4.14 million
Optionable
Not Optionable
Beta
1.96

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:CYTR) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners